All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

TY - BOOK

T1 - All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

AU - Hughes, D.

AU - Hughes, D.A.

AU - All Wales Strategy Group., [No Value]

PY - 2008/1/1

Y1 - 2008/1/1

UR - http://www.wales.nhs.uk/sites3/Documents/371/icatibant%20_Firazyr_%20FAR%20revised_Jerini%20CIC%20check.pdf

M3 - Commissioned report

BT - All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

PB - Unknown

ER -